Fixed Dose of Cemiplimab in Patients with Advanced Malignancies based on Population Pharmacokinetic Analysis
figureposted on 2021-03-04, 17:38 authored by Adis journals on behalf of, Anne J. Paccaly, Michael R. Migden, Kyriakos P. Papadopoulos, Feng Yang, John D. Davis, Ronda K. Rippley, Israel Lowy, Matthew G. Fury, Elizabeth Stankevich, Danny Rischin
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.